The Gastrointestinal Therapeutics and Diagnostics Market is expected to register a CAGR of 7% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The Gastrointestinal Therapeutics and Diagnostics Market report covers segmental analysis by Application (Diagnostics, Therapeutics); Condition (Gastroenteritis, GI Bleeding, Irritable Bowel Syndrome, Peptic Ulcer Disease (PUD), Others), and Geography (North America, Europe, Asia Pacific, and South and Central America). The global analysis is further broken down at the regional level and major countries. The report Offers the Value in US$ for the above analysis and segments.
Purpose of the ReportThe report Gastrointestinal Therapeutics and Diagnostics Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Gastrointestinal Therapeutics and Diagnostics Market Segmentation
Application- Diagnostics
- Therapeutics
- Gastroenteritis
- GI Bleeding
- Irritable Bowel Syndrome
- Peptic Ulcer Disease
Strategic Insights
Gastrointestinal Therapeutics and Diagnostics Market Growth Drivers- Expansion of GI Therapeutic Pipeline: The development of novel drugs and biologics for treating gastrointestinal diseases, especially those targeting inflammatory conditions and gut microbiota, is driving the growth of the Gastrointestinal Therapeutics and Diagnostics market. Companies are increasingly focused on personalized medicine and precision therapies, aiming to deliver more effective, targeted treatments with fewer side effects. Ongoing research in areas such as immunotherapy and gene therapies is opening new avenues for the treatment of chronic GI disorders, offering significant market potential.
- Rising Demand for Minimally Invasive Procedures: As patients seek less invasive treatment options, the demand for minimally invasive diagnostic procedures like endoscopies and biopsies has surged. These procedures, often guided by advanced imaging and diagnostic tools, are less risky and allow for quicker recovery times compared to traditional surgeries. The increasing preference for minimally invasive treatments is fueling the growth of the Gastrointestinal Therapeutics and Diagnostics market, particularly in diagnostic categories such as endoscopic ultrasound, colonoscopies, and capsule endoscopy.
- Rising Healthcare Expenditure and Infrastructure Development: Growing healthcare expenditures, particularly in emerging markets, are contributing to the expansion of the Gastrointestinal Therapeutics and Diagnostics market. Countries with improving healthcare infrastructures are investing in advanced diagnostic equipment, which leads to better access to early-stage diagnostics for GI disorders. The development of state-of-the-art healthcare facilities in regions like Asia-Pacific and Latin America is helping address the rising demand for gastrointestinal diagnostics and therapeutics in these regions.
- Non-Invasive Diagnostic Innovations: The demand for non-invasive diagnostic methods in the Gastrointestinal Therapeutics and Diagnostics market is expected to rise. Technologies such as breath tests, blood-based biomarkers, and imaging techniques like MRI and CT scans will replace or complement traditional methods like endoscopies and colonoscopies. These innovations promise less discomfort, reduced risk, and faster recovery for patients, making them increasingly attractive. Non-invasive diagnostics will also open up new possibilities for routine screenings, especially for conditions like colorectal cancer and liver diseases, contributing to the early detection and better management of GI disorders.
- Growth in Home Diagnostics and Remote Monitoring: The future of gastrointestinal diagnostics will likely see a significant increase in home-based testing and remote monitoring solutions. With the rise of telemedicine and wearable health technologies, patients will be able to monitor their GI health from the comfort of their homes. Remote monitoring tools that track symptoms of GI diseases like Crohn’s disease and IBS will enable doctors to adjust treatment plans in real time. This trend toward at-home diagnostics and personalized remote care will drive the expansion of the market, providing a more patient-centered approach and reducing the need for frequent hospital visits.
- Biologic Therapies and Immunotherapies Expansion: The future of gastrointestinal therapeutics will see an increased reliance on biologic therapies and immunotherapies. With their ability to target specific pathways and immune responses involved in GI diseases, biologics are set to become a cornerstone of treatment for conditions like Crohn’s disease, ulcerative colitis, and colorectal cancer. Future trends indicate a rise in the use of monoclonal antibodies, tumor necrosis factor inhibitors (TNFi), and other biologics that are customized to treat different subtypes of GI disorders. The market will also see breakthroughs in combination therapies that enhance the efficacy of biologics and immunotherapies, improving patient outcomes in complex gastrointestinal diseases.
- Increased Focus on Gut Health and Microbiome Therapies: The growing understanding of the role of the gut microbiome in overall health presents an exciting opportunity for growth in the Gastrointestinal Therapeutics and Diagnostics market. As the connection between gut health and conditions like obesity, diabetes, and autoimmune diseases becomes clearer, there is increasing interest in developing microbiome-based therapeutics, including probiotics, prebiotics, and fecal microbiota transplants (FMT). These therapies have the potential to treat chronic GI conditions more effectively and can be integrated into personalized treatment plans. The market for microbiome-based diagnostics is also expanding, with companies exploring microbiome profiling tools that can guide targeted therapies.
- Opportunities in Gastrointestinal Cancer Diagnostics and Treatments: The rising incidence of gastrointestinal cancers, including colorectal cancer, liver cancer, and pancreatic cancer, creates a significant opportunity in the Gastrointestinal Therapeutics and Diagnostics market. Innovations in early diagnostic tests, such as liquid biopsies, genetic testing, and advanced imaging, will allow for earlier detection and improved treatment outcomes. Furthermore, advancements in immunotherapy and targeted biologics are expected to provide more effective treatment options for GI cancers. Companies developing diagnostic tools and cancer-specific therapies will benefit from the growing demand for comprehensive cancer care and the need for earlier, more accurate diagnostics.
- Regulatory Support for Advanced Gastrointestinal Therapies: Regulatory bodies, such as the FDA and EMA, are offering expedited approval pathways for innovative gastrointestinal therapeutics and diagnostics, especially those addressing unmet medical needs. This regulatory support creates an opportunity for companies to bring new treatments to market faster and more efficiently. As authorities continue to prioritize innovations in GI healthcare, companies in the Gastrointestinal Therapeutics and Diagnostics market can benefit from these accelerated approval processes, reducing time-to-market and enhancing their competitive edge in the industry.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Gastrointestinal Therapeutics and Diagnostics Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Gastrointestinal Therapeutics and Diagnostics Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?
Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Gastrointestinal Therapeutics and Diagnostics Market is expected to register a CAGR of 7% from 2025-2031.
The major factors impacting the Gastrointestinal Therapeutics and Diagnostics Market are: Expansion of GI Therapeutic Pipeline, Rising Demand for Minimally Invasive Procedures and Rising Healthcare Expenditure and Infrastructure Development
Key future trends in this market are - Non-Invasive Diagnostic Innovations, Growth in Home Diagnostics and Remote Monitoring and Biologic Therapies and Immunotherapies Expansion
Key companies of this market are: Abbott Laboratories, AstraZeneca, Eisai Co., Ltd., Johnson and Johnson, Salix Pharmaceuticals, Takeda Pharmaceuticals Company, Bayer AG, GlaxoSmithKline, Valeant Pharmaceuticals, AbbVie, Inc.
The report can be delivered in PDF/PPT format; we can also share excel dataset based on the request.
Some of the customization options available based on request are additional 3–5 company profiles and country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation, as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Gastrointestinal Therapeutics And Diagnostics Market - By Application
1.3.2 Gastrointestinal Therapeutics And Diagnostics Market - By Condition
1.3.3 Gastrointestinal Therapeutics And Diagnostics Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS MARKET - GLOBAL MARKET ANALYSIS
6.1. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS - GLOBAL MARKET OVERVIEW
6.2. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - APPLICATION
7.1. OVERVIEW
7.2. APPLICATION MARKET FORECASTS AND ANALYSIS
7.3. DIAGNOSTICS
7.3.1. Overview
7.3.2. Diagnostics Market Forecast and Analysis
7.4. THERAPEUTICS
7.4.1. Overview
7.4.2. Therapeutics Market Forecast and Analysis
8. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS MARKET - REVENUE AND FORECASTS TO 2028 - CONDITION
8.1. OVERVIEW
8.2. CONDITION MARKET FORECASTS AND ANALYSIS
8.3. GASTROENTERITIS
8.3.1. Overview
8.3.2. Gastroenteritis Market Forecast and Analysis
8.4. GI BLEEDING
8.4.1. Overview
8.4.2. GI Bleeding Market Forecast and Analysis
8.5. IRRITABLE BOWEL SYNDROME
8.5.1. Overview
8.5.2. Irritable Bowel Syndrome Market Forecast and Analysis
8.6. PEPTIC ULCER DISEASE (PUD)
8.6.1. Overview
8.6.2. Peptic Ulcer Disease (PUD) Market Forecast and Analysis
8.7. OTHERS
8.7.1. Overview
8.7.2. Others Market Forecast and Analysis
9. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Gastrointestinal Therapeutics And Diagnostics Market Overview
9.1.2 North America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis
9.1.3 North America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Application
9.1.4 North America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Condition
9.1.5 North America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Countries
9.1.5.1 United States Gastrointestinal Therapeutics And Diagnostics Market
9.1.5.1.1 United States Gastrointestinal Therapeutics And Diagnostics Market by Application
9.1.5.1.2 United States Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.1.5.2 Canada Gastrointestinal Therapeutics And Diagnostics Market
9.1.5.2.1 Canada Gastrointestinal Therapeutics And Diagnostics Market by Application
9.1.5.2.2 Canada Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.1.5.3 Mexico Gastrointestinal Therapeutics And Diagnostics Market
9.1.5.3.1 Mexico Gastrointestinal Therapeutics And Diagnostics Market by Application
9.1.5.3.2 Mexico Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.2. EUROPE
9.2.1 Europe Gastrointestinal Therapeutics And Diagnostics Market Overview
9.2.2 Europe Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis
9.2.3 Europe Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Application
9.2.4 Europe Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Condition
9.2.5 Europe Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Gastrointestinal Therapeutics And Diagnostics Market
9.2.5.1.1 Germany Gastrointestinal Therapeutics And Diagnostics Market by Application
9.2.5.1.2 Germany Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.2.5.2 France Gastrointestinal Therapeutics And Diagnostics Market
9.2.5.2.1 France Gastrointestinal Therapeutics And Diagnostics Market by Application
9.2.5.2.2 France Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.2.5.3 Italy Gastrointestinal Therapeutics And Diagnostics Market
9.2.5.3.1 Italy Gastrointestinal Therapeutics And Diagnostics Market by Application
9.2.5.3.2 Italy Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.2.5.4 Spain Gastrointestinal Therapeutics And Diagnostics Market
9.2.5.4.1 Spain Gastrointestinal Therapeutics And Diagnostics Market by Application
9.2.5.4.2 Spain Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.2.5.5 United Kingdom Gastrointestinal Therapeutics And Diagnostics Market
9.2.5.5.1 United Kingdom Gastrointestinal Therapeutics And Diagnostics Market by Application
9.2.5.5.2 United Kingdom Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.2.5.6 Rest of Europe Gastrointestinal Therapeutics And Diagnostics Market
9.2.5.6.1 Rest of Europe Gastrointestinal Therapeutics And Diagnostics Market by Application
9.2.5.6.2 Rest of Europe Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market Overview
9.3.2 Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis
9.3.3 Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Application
9.3.4 Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Condition
9.3.5 Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Gastrointestinal Therapeutics And Diagnostics Market
9.3.5.1.1 Australia Gastrointestinal Therapeutics And Diagnostics Market by Application
9.3.5.1.2 Australia Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.3.5.2 China Gastrointestinal Therapeutics And Diagnostics Market
9.3.5.2.1 China Gastrointestinal Therapeutics And Diagnostics Market by Application
9.3.5.2.2 China Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.3.5.3 India Gastrointestinal Therapeutics And Diagnostics Market
9.3.5.3.1 India Gastrointestinal Therapeutics And Diagnostics Market by Application
9.3.5.3.2 India Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.3.5.4 Japan Gastrointestinal Therapeutics And Diagnostics Market
9.3.5.4.1 Japan Gastrointestinal Therapeutics And Diagnostics Market by Application
9.3.5.4.2 Japan Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.3.5.5 South Korea Gastrointestinal Therapeutics And Diagnostics Market
9.3.5.5.1 South Korea Gastrointestinal Therapeutics And Diagnostics Market by Application
9.3.5.5.2 South Korea Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.3.5.6 Rest of Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market
9.3.5.6.1 Rest of Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market by Application
9.3.5.6.2 Rest of Asia-Pacific Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market Overview
9.4.2 Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis
9.4.3 Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Application
9.4.4 Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Condition
9.4.5 Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Gastrointestinal Therapeutics And Diagnostics Market
9.4.5.1.1 South Africa Gastrointestinal Therapeutics And Diagnostics Market by Application
9.4.5.1.2 South Africa Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.4.5.2 Saudi Arabia Gastrointestinal Therapeutics And Diagnostics Market
9.4.5.2.1 Saudi Arabia Gastrointestinal Therapeutics And Diagnostics Market by Application
9.4.5.2.2 Saudi Arabia Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.4.5.3 U.A.E Gastrointestinal Therapeutics And Diagnostics Market
9.4.5.3.1 U.A.E Gastrointestinal Therapeutics And Diagnostics Market by Application
9.4.5.3.2 U.A.E Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.4.5.4 Rest of Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market
9.4.5.4.1 Rest of Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market by Application
9.4.5.4.2 Rest of Middle East and Africa Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Gastrointestinal Therapeutics And Diagnostics Market Overview
9.5.2 South and Central America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis
9.5.3 South and Central America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Application
9.5.4 South and Central America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Condition
9.5.5 South and Central America Gastrointestinal Therapeutics And Diagnostics Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Gastrointestinal Therapeutics And Diagnostics Market
9.5.5.1.1 Brazil Gastrointestinal Therapeutics And Diagnostics Market by Application
9.5.5.1.2 Brazil Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.5.5.2 Argentina Gastrointestinal Therapeutics And Diagnostics Market
9.5.5.2.1 Argentina Gastrointestinal Therapeutics And Diagnostics Market by Application
9.5.5.2.2 Argentina Gastrointestinal Therapeutics And Diagnostics Market by Condition
9.5.5.3 Rest of South and Central America Gastrointestinal Therapeutics And Diagnostics Market
9.5.5.3.1 Rest of South and Central America Gastrointestinal Therapeutics And Diagnostics Market by Application
9.5.5.3.2 Rest of South and Central America Gastrointestinal Therapeutics And Diagnostics Market by Condition
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. GASTROINTESTINAL THERAPEUTICS AND DIAGNOSTICS MARKET, KEY COMPANY PROFILES
11.1. ABBOTT LABORATORIES
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. ASTRAZENECA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. EISAI CO., LTD
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. JOHNSON AND JOHNSON
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. SALIX PHARMACEUTICALS
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. TAKEDA PHARMACEUTICAL COMPANY
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. BAYER AG
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. GLAXOSMITHKLINE
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. VALEANT PHARMACEUTICALS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. ABBVIE, INC
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
1. Abbott Laboratories
2. AstraZeneca
3. Eisai Co., Ltd
4. Johnson and Johnson
5. Salix Pharmaceuticals
6. Takeda Pharmaceutical Company
7. Bayer AG
8. GlaxoSmithKline
9. Valeant Pharmaceuticals
10. AbbVie, Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For